Shanghai Pharmaceuticals Holding Co Ltd banner

Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607

Watchlist Manager
Shanghai Pharmaceuticals Holding Co Ltd Logo
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Watchlist
Price: 17.16 CNY -0.29% Market Closed
Market Cap: ¥63.6B

EV/EBIT

15.2
Current
53%
More Expensive
vs 3-y median of 9.9

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
15.2
=
Enterprise Value
¥113.2B
/
EBIT
¥7.5B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
15.2
=
Enterprise Value
¥113.2B
/
EBIT
¥7.5B

Valuation Scenarios

Shanghai Pharmaceuticals Holding Co Ltd is trading above its 3-year average

If EV/EBIT returns to its 3-Year Average (9.9), the stock would be worth ¥11.23 (35% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-38%
Maximum Upside
+94%
Average Upside
28%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 15.2 ¥17.16
0%
3-Year Average 9.9 ¥11.23
-35%
5-Year Average 9.4 ¥10.57
-38%
Industry Average 29.4 ¥33.24
+94%
Country Average 28.9 ¥32.67
+90%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
¥113.2B
/
Oct 2025
¥7.5B
=
15.2
Current
¥113.2B
/
Dec 2025
¥10.2B
=
11.1
Forward
¥113.2B
/
Dec 2026
¥10.1B
=
11.2
Forward
¥113.2B
/
Dec 2027
¥11.3B
=
10
Forward
¥113.2B
/
Dec 2028
¥11B
=
10.3
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close

Market Distribution

Lower than 74% of companies in China
Percentile
26th
Based on 5 337 companies
26th percentile
15.2
Low
0 — 16.6
Typical Range
16.6 — 52.9
High
52.9 —
Distribution Statistics
China
Min 0
30th Percentile 16.6
Median 28.9
70th Percentile 52.9
Max 49 021

Shanghai Pharmaceuticals Holding Co Ltd
Glance View

Market Cap
63.6B CNY
Industry
Health Care

Shanghai Pharmaceuticals Holding Co Ltd, a giant in China's pharmaceutical industry, operates with a dual-engine strategy that seamlessly combines manufacturing and distribution. Established in the bustling metropolis of Shanghai, the company has swiftly become a cornerstone of China's healthcare landscape. Its manufacturing arm is a powerhouse of innovation and production, turning out a vast array of pharmaceutical products that encompass both traditional Chinese medicine and modern pharmaceuticals. These products range from patented medicines to essential generics, entering hospitals, clinics, and retail pharmacies nationwide, all the while feeding a robust supply chain that caters to the country's vast and diverse market needs. On the flip side, Shanghai Pharmaceuticals' extensive distribution network is the lifeline that ensures these vital medicines reach their destinations safely and efficiently. In an era where logistics and supply chain management are pivotal, the company excels through an advanced distribution system that connects manufacturers with end-users across China. This network is bolstered by strategic partnerships and a commitment to technological advancement, allowing the company to maintain agility and reliability in an ever-evolving market. Revenue streams flow not just from product sales but are heavily supplemented through strategic partnerships and services that enhance accessibility and affordability for healthcare providers and patients alike. As one of the top pharmaceutical firms in China, Shanghai Pharmaceuticals is adept at maneuvering the intricacies of healthcare demands, regulatory landscapes, and competitive dynamics, carving its niche as a leader in both innovation and distribution efficiency.

Intrinsic Value
34.32 CNY
Undervaluation 50%
Intrinsic Value
Price